A Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy Study

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• In vivo mouse models are crucial for translating cancer research to human therapies.
• Existing models often lack long-term observation and accurate patient condition mimicry.
• Metastatic melanoma research requires robust immunocompetent models for evaluating new treatments.

Purpose of the Study:

• To assess longitudinal treatment response in a transgenic mouse model of metastatic melanoma.
• To evaluate the efficacy of troriluzole (a glutamatergic signaling inhibitor) and anti-PD-1 (immune checkpoint inhibitor) therapy.
• To investigate potential sex-biased responses in melanoma treatment.

Main Methods:

• Utilized a fully immunocompetent, transgenic mouse model (TGS) with spontaneous metastatic melanoma.
• Administered troriluzole and/or anti-PD-1 antibody for up to 8 months.
• Analyzed treatment response, survival rates, and immune cell populations (CD8+ T cells, CD11b+ myeloid cells).

Main Results:

• A significant sex-biased treatment response was observed.
• Male mice exhibited improved survival rates when treated with troriluzole and/or anti-PD-1.
• Differential immune cell populations at the tumor-stromal interface correlated with improved survival in males.

Conclusions:

• The TGS mouse model is a responsive and tractable system for evaluating melanoma therapeutic regimens.
• Troriluzole and anti-PD-1 therapy demonstrate efficacy in an immunocompetent setting, with notable sex differences.
• Further research into sex-biased immune responses in melanoma is warranted.